Strategic partnerships Opportunity to leverage existing license with Bayer for ERSO to co-develop or expand to additional targets in metastatic ER-positive breast cancer and other polygenic diseases, accelerating pipeline progression with a credible pharma partner.

AI driven discovery Position to offer AI-enabled drug discovery capabilities to pharmaceutical and biotech clients seeking rapid target silencing or multimodal RNA therapies, potentially providing contract research or collaboration for precision oncology programs.

Small team agility With a compact team and high-value partnerships, there is a market niche for strategic manufacturing and clinical development services, outsourcing components of early-stage programs to Systems Oncology’s Arromer platform and its self-delivering therapeutics.

Niche oncology focus Strong appeal to mid-market biotechs seeking breakthrough RNA-based modalities; opportunities to position as a partner for late-stage validation or translational studies in oncology, leveraging the multimo dal RNA platform.

Evidence of recognition Prior awards and media visibility in AI for drug discovery bolster credibility with potential customers and investors, creating openings for speaking engagements, joint webinars, and strategic collaborations that seed deal flow.